Organovo to Test Pre-Clinical Drugs on Bio-Printed Kidney Tissue
Xconomy
SEPTEMBER 9, 2016
It’s been almost two years since Organovo (NYSE: ONVO ) created a new business—using its bio-printing technology to create 3-D samples of living human liver tissue for use in testing the toxicity of pre-clinical drug candidates. The company said it has signed multiple commercial orders for its kidney drug-testing service.
40 
Let's personalize your content